Digraph

2019-07 FDA approval of imipenem/cilastatin plus relebactam
FDA approves new treatment for complicated urinary tract and complicated intra-abdominal infections | FDAhttps://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-complicated-urinary-tract-and-complicated-intra-abdominal-infections
2019-07 FDA approval of imipenem/cilastatin plus relebactam
Keith Kaye on of Imipenem/Cilastatin + Relebactam | ContagionLivehttps://www.contagionlive.com/news/keith-kaye-md-mph-on-the-approval-of-imipenemcilastatin--relebactam
2019-07 FDA approval of imipenem/cilastatin plus relebactam
Keith Kaye, MD, MPH, on the Approval of Imipenem/Cilastatin + Relebactamhttps://www.contagionlive.com/publications/contagion/2019/december/keith-kaye-md-mph-on-the-approval-of-imipenemcilastatin--relebactam
2019-07 FDA approval of imipenem/cilastatin plus relebactamAmpC cephalosporinaseExtended spectrum beta-lactamases (ESBL)Klebsiella pneumoniae carbapenemase (KPC)

Showing topic

2019-07 FDA approval of imipenem/cilastatin plus relebactam
Antibiotic-resistant urinary tract infections (UTIs)Imipenem-cilastatin-relebactamPharmaceutical makers, antibiotic resistance and the development of new drugs